MedTrace Logo

Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer

NCT02375035 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-03-02

No results posted yet for this study

Summary

To evaluate the use of the CAMbridge PROstate Biopsy devicE (CAMPROBE) as a method of undertaking prostate biopsy as part of their clinical management.

Conditions

Interventions

DEVICE

CAMPROBE

To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Vincent Gnanapragasam · University of Cambridge

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31
Completion
2019-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02375035 on ClinicalTrials.gov